James Shannon

James Samuel Shannon currently works at MannKind Corp., as Chairman from 2020, ProQR Therapeutics NV, as Chairman-Supervisory Board from 2024, Impatients NV, as Chairman from 2016, Kyowa Kirin Ltd., as Chairman from 2019, Mytommorows, as Director, Xilio Therapeutics, Inc., as Independent Director from 2024, The Royal College of Physicians, as Member, and Leyden Laboratories BV, as Member-Supervisory Board from 2020.
Dr. Shannon also formerly worked at Cerimon Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2009 to 2010, MannKind Corp., as Independent Director from 2011 to 2012, Circassia Ltd., as Non-Executive Director, Horizon Therapeutics Ltd. (Ireland), as Independent Director from 2017 to 2023, Biotie Therapies Oy, as Director from 2010 to 2012, Xanodyne Pharmaceuticals, Inc., as Director, Endocyte, Inc., as Independent Director from 2010 to 2012, Immodulon Therapeutics Ltd., as Director from 2016 to 2021, Arch Therapeutics, Inc., as Director, ViiV Healthcare Ltd., as Director, Crucell NV, as Member-Supervisory Board from 2010 to 2011, GSK Plc, as Chief Medical Officer from 2012 to 2015, Sterling Winthrop, Inc., as Senior Vice President-Clinical Development from 1987 to 1994, Sandoz Ltd., as Head-Drug Regulatory Affairs in 1995, and Novartis Pharma AG, as Global Head-Pharmaceutical Development from 1994 to 2008.
Dr. Shannon received his undergraduate degree, graduate degree, and doctorate degree from Queen's University of Belfast.